NEW YORK, July 26 (Reuters) - OSI Pharmaceuticals shares could benefit as the Melville, N.Y.-based company expands the uses of its lung-cancer drug, Barron's said.
OSI's sales of Tarceva, the second-largest oral anti-cancer drug, hit $1 billion last year.
OSI trades for about $32 a share, about 18 times next year's earnings, Barron's said, projecting it could rally to $45 a share in the coming year with the help of Tarceva.
(Reporting by Steve Eder)
((Reuters email: steve.eder@reuters.com; +1 646 223 6069)) Keywords: OSI/SHARES (For help: Click 'Contact Us' in your desk top, click here or call 1-800-738-8377 for Reuters Products and 1-888-463-3383 for Thomson products; For client training: training.americas@thomsonreuters.com; +1 646-223-5546) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
OSI's sales of Tarceva, the second-largest oral anti-cancer drug, hit $1 billion last year.
OSI trades for about $32 a share, about 18 times next year's earnings, Barron's said, projecting it could rally to $45 a share in the coming year with the help of Tarceva.
(Reporting by Steve Eder)
((Reuters email: steve.eder@reuters.com; +1 646 223 6069)) Keywords: OSI/SHARES (For help: Click 'Contact Us' in your desk top, click here or call 1-800-738-8377 for Reuters Products and 1-888-463-3383 for Thomson products; For client training: training.americas@thomsonreuters.com; +1 646-223-5546) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.